ArticleScientific reports2025
Cathepsin B as a potential serum biomarker for early diagnosis and progression of diabetic foot ulcer complicated with peripheral vascular disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The existing diagnostic methods of diabetic foot ulcer (DFU) complicated with peripheral vascular disease (PVD) lack sufficient potential for early identification, which leads to slow wound healing, amputation and even death. Thus, this study aimed to explore the potential serum biomarkers of DFU complicated with PVD. A target gene of DFU complicated with PVD was identified using single-cell transcriptome analysis. The immunohistochemistry, ELISA, clinical correlation analysis, tubulogenesis assay, CCK8 assay, and scratch assay were used to verify the correlation between this target gene and DFU complicated with PVD. The ELISA experiment was used to detect the target gene in serum. In this study, the result of PPI in single-cell transcriptomes showed that cathepsin B (CTSB) was enriched in vascular endothelial cells of DFU. The immunohistochemistry and ELISA results revealed that CTSB was highly expressed in the tissues and serum of patients with the combination of DFU and PVD, and this expression increased with the increase of the Wagner grade of DFU. Clinical correlation analysis indicated that CTSB expression is positively correlated with the clinical indicators of the combination of DFU and PVD. Knockdown of CTSB promoted tubulogenesis, proliferation and migration of vascular endothelial cells and overexpression of CTSB has the opposite effect. CTSB, a secretory protein, can be detected as a diagnostic biomarker in serum. Therefore, this study suggested that CTSB can be used as a potential serum diagnostic biomarker for DFU complicated with PVD, which is helpful for the early diagnosis of this disease, prognosis monitoring and adjustment of treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.